A four-drug chemotherapy regimen provided longer overall survival than a two-drug combination in a Phase 3 clinical trial for metastatic pancreatic ductal adenocarcinoma.
MINNEAPOLIS, Jan. 19, 2023). Previously, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to SBP-101. "We are pleased to receive notice that the European Commission has adopted
NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel